383 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards? http://www.zacks.com/stock/news/223906/illumina-ilmn-to-report-q2-earnings-whats-in-the-cards?cid=CS-ZC-FT-223906 Jul 19, 2016 - Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today? http://www.zacks.com/stock/news/223342/why-are-allergan-agn-and-teva-pharma-teva-stocks-up-today?cid=CS-ZC-FT-223342 Jul 13, 2016 - On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
Top 7 Research Reports for July 15, 2016 http://www.zacks.com/research-daily/86015/top-7-research-reports-for-july-15-2016?cid=CS-ZC-FT-86015 Jul 15, 2016 - Top 7 Research Reports for July 15, 2016
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain http://www.zacks.com/stock/news/223394/teva-teva-provides-2016-2019-outlook-shares-gain?cid=CS-ZC-FT-223394 Jul 14, 2016 - Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
What Awaits Boston Scientific (BSX) in Q2 Earnings? http://www.zacks.com/stock/news/224050/what-awaits-boston-scientific-bsx-in-q2-earnings?cid=CS-ZC-FT-224050 Jul 19, 2016 - Boston Scientific Corporation (BSX) is scheduled to report its second-quarter 2016 results before the opening bell on Jul 28.
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted http://www.zacks.com/stock/news/252134/aerie-aeri-q4-loss-widens-rhopressa-nda-resubmitted?cid=CS-ZC-FT-252134 Mar 08, 2017 - Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA http://www.zacks.com/stock/news/252294/allergans-agn-vraylar-snda-accepted-for-review-by-fda?cid=CS-ZC-FT-252294 Mar 09, 2017 - Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod http://www.zacks.com/stock/news/253593/allergans-dermal-filler-for-wrinkle-correction-gets-fda-nod?cid=CS-ZC-FT-253593 Mar 21, 2017 - Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
Allergan (AGN) Enters Strategic Alliance With Editas Medicine (EDIT) - Slideshow http://seekingalpha.com/article/4055538-allergan-agn-enters-strategic-alliance-editas-medicine-edit-slideshow?source=feed_sector_healthcare Mar 15, 2017 - The following slide deck was published by Allergan plc in conjunction with this event.

Pages: 123456789...39

<<<Page 4>